



7-9-07

WV

Express Mail No. EV 922 265 313 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: LaColla *et al.*

Confirmation No. 1837

Serial No.: 10/806,295

Art Unit: 1617

Filed: March 22, 2004

Examiner: Leonard M Williams

For: PHENYLINDOLES FOR THE
TREATMENT OF HIV

Attorney Docket No: IDX 1008 DIV
(New Docket No. 11874-076-999)

TRANSMITTAL LETTER

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:


Transmitted herewith for filing in the above-referenced application are the following documents:

1. Executed Revocations and Powers of Attorney by Assignees and Statements Under 37 C.F.R. § 3.73(b); and
2. Copies of Assignment Papers – cover sheets & documents.

Please charge any required fees to Jones Day Deposit Account No. 50-3013. A copy of this sheet is enclosed.

Respectfully submitted,

Date: July 5, 2007


Rahul Pathak 42,983
(Reg. No.)
For: Anthony M. Insogna (Reg. No. 35,203)

Enclosures

JONES DAY
222 East 41st Street
New York, New York 10017
(858) 314-1200



POWER OF ATTORNEY

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: LaColla *et al.* Confirmation No. 1837
Serial No.: 10/806,295 Art Unit: 1617
Filed: March 22, 2004 Examiner: Leonard M Williams
For: PHENYLINDOLES FOR THE TREATMENT OF HIV Attorney Docket No: IDX 1008 DIV
(New Docket No. 11874-076-999)

**REVOCATION AND POWER OF ATTORNEY AND
STATEMENT UNDER 37 C.F.R. 3.73(b)**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

IDENIX PHARMACEUTICALS, INC. (assignee) hereby revokes any and all previous powers and appoints:

☒ Practitioners at Customer Number **20583**

to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.

Please direct all correspondence addressed for the above-identified application to:

☒ The above mentioned Customer Number.

☒ Firm or Individual Name:

Address: Jones Day, 222 East 41st Street, New York, New York 10017

Telephone: (212) 901-9028

I am the:

- ☐ Applicant/Inventor
☒ Assignee of record of less than the entire interest. See 37 CFR 3.71.
(Statement under 37 CFR 3.73(b) is applicable)

STATEMENT UNDER 37 C.F.R. 3.73(b)

IDENIX PHARMACEUTICALS, INC. states that it is, along with Università Degli Studi Di Cagliari, is co-assignee of the patent application/patent identified above by virtue of a chain of title from the inventor(s), to the current assignees as shown below:


1. Inventors Paolo LaColla and Marino Artico assigned their interest to Università Degli Studi Di Cagliari and inventor Jean-Pierre Sommadossi assigned his interest to Novirio Pharmaceuticals Limited in the parent patent application U.S. Patent Application No. 10/122,252, filed April 11, 2002, now U.S. Patent No. 6,710,068, and continuations, divisionals and continuations-in-part thereof, which was recorded in the United States Patent and Trademark Office on April 11, 2002, at Reel 012809, Frame 0969.
2. The change of name from Novirio Pharmaceuticals Limited to Idenix Pharmaceuticals, Inc. was recorded in the United States Patent and Trademark Office on August 19, 2002, at Reel 013193, Frame 0841, and a Certificate of Domestic Incorporation in Delaware was recorded on February 6, 2003, at Reel 013718, Frame 0543.

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

ASSIGNEE: IDENIX PHARMACEUTICALS, INC.

Date: April 9, 2007

Signature:



Typed Name:

Position/Title:

**JEAN-PIERRE SOMMADOSSI, Ph.D.
CHAIRMAN AND CEO
IDENIX PHARMACEUTICALS, INC.**



POWER OF ATTORNEY

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: LaColla *et al.* Confirmation No. 1837
Serial No.: 10/806,295 Art Unit: 1617
Filed: March 22, 2004 Examiner: Leonard M Williams
For: PHENYLINDOLES FOR THE TREATMENT OF HIV Attorney Docket No: IDX 1008 DIV
(New Docket No. 11874-076-999)

**REVOCATION AND POWER OF ATTORNEY AND
STATEMENT UNDER 37 C.F.R. 3.73(b)**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

UNIVERSITA DEGLI STUDI DI CAGLIARI (assignee) hereby revokes any and all previous powers and appoints:

☒ Practitioners at Customer Number 20583

to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.

Please direct all correspondence addressed for the above-identified application to:

☒ The above mentioned Customer Number.

☒ Firm or Individual Name:

Address: Jones Day, 222 East 41st Street, New York, New York 10017

Telephone: (212) 901-9028

I am the:

☐

Applicant/Inventor

☒

Assignee of record of less than the entire interest. See 37 CFR 3.71.
(Statement under 37 CFR 3.73(b) is applicable)

STATEMENT UNDER 37 C.F.R. 3.73(b)

UNIVERSITA DEGLI STUDI DI CAGLIARI states that it is, along with Idenix Pharmaceuticals, Inc., is co-assignee of the patent application/patent identified above by virtue of a chain of title from the inventor(s), to the current assignees as shown below:

1. Inventors Paolo LaColla and Marino Artico assigned their interest to Università Degli Studi Di Cagliari and inventor Jean-Pierre Sommadossi assigned his interest to Novirio Pharmaceuticals Limited in the parent patent application U.S. Patent Application No. 10/122,252, filed April 11, 2002, now U.S. Patent No. 6,710,068, and continuations, divisionals and continuations-in-part thereof, which was recorded in the United States Patent and Trademark Office on April 11, 2002, at Reel 012809, Frame 0969.
2. The change of name from Novirio Pharmaceuticals Limited to Idenix Pharmaceuticals, Inc. was recorded in the United States Patent and Trademark Office on August 19, 2002, at Reel 013193, Frame 0841, and a Certificate of Domestic Incorporation in Delaware was recorded on February 6, 2003, at Reel 013718, Frame 0543.

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

ASSIGNEE: UNIVERSITA DEGLI STUDI DI CAGLIARI

Date: 12 APR. 2007

Signature: _____


Typed Name: _____

Position/Title: _____

Certifico io Ufficiale Rogante Sostituto dell'Università degli Studi di Cagliari che la firma, apposta in mia presenza dal Prof. Adolfo Lai nato a Ottana il 28.07.1943, Pro Rettore dell'Università di Cagliari e della cui identità personale sono certo, è autentica

L'Ufficiale Rogante Sostituto
Dr. Achille Filiberto Putzu





UNITED STATES
PATENT AND
TRADEMARK OFFICE

06171. IAX/008US

JUNE 19, 2002

PTAS

Chief Information Officer
Washington, DC 20231
www.uspto.gov

SHERRY M. KNOWLES, ESQ.
191 PEACHTREE STREET
ATLANTA, GEORGIA 30303-1763



102065015A

UNITED STATES PATENT AND TRADEMARK OFFICE
NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT DIVISION OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE MICROFILM COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE EMPLOYEE WHOSE NAME APPEARS ON THIS NOTICE AT 703-308-9723. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, ASSIGNMENT DIVISION, BOX ASSIGNMENTS, CG-4, 1213 JEFFERSON DAVIS HWY, SUITE 320, WASHINGTON, D.C. 20231.

RECORDATION DATE: 04/11/2002

REEL/FRAME: 012809/0969
NUMBER OF PAGES: 8

BRIEF: ASSIGNMENT OF ASSIGNOR'S INTEREST (SEE DOCUMENT FOR DETAILS).

ASSIGNOR:
LACOLLA, PAOLO

DOC DATE: 06/22/2001


ASSIGNOR:
ARTICO, MARINO

DOC DATE: 06/20/2001

ASSIGNOR:
SOMMANDOSSY, PIERRE

DOC DATE: 06/23/2001

ASSIGNEE:
NOVIRIO PHARMACEUTICALS LIMITED
125 CAMBRIDGE PARK DR.
C/O WALKER SECRETARIES, WALKER
HOUSE, MARY STREET, GRAND
CAYMAN, CAYMAN ISLANDS
CAMBRIDGE, MASSACHUSETTS 02140



012809/0969 PAGE 2

ASSIGNEE:

UNIVERSITA DEGLI STUDI DI CAGLIARI
SEZIONE DI MICROBIOLOGIA
CITTADELLA UNIVERSITARIA SS 554,
KM. 4.500
09042 MONSERRATO (CA), ITALY

SERIAL NUMBER: 10122252
PATENT NUMBER:

FILING DATE: 04/11/2002
ISSUE DATE:

THERESA FREDERICK, EXAMINER
ASSIGNMENT DIVISION
OFFICE OF PUBLIC RECORDS

Second receiving party(ies):

UNIVERSITA' DEGLI STUDI DI CAGLIARI

Sezione di Microbiologia

Cittadella Universitaria SS 554, Km. 4.500

09042 MONSERRATO (CA) Italy

ASSIGNMENT


WHEREAS, WE, PAULO LA COLLA, MARINO ARTICO, AND JEAN-PIERRE SOMMADOSSI, have invented certain improvements in "Phenylindoles for the Treatment of HIV" for which We/I have executed United States Provisional Application No. 60/283,393 which was filed on April 11, 2001; and

WHEREAS, **Universita Degli Studi Di Cagliari**, with a mailing address of Cittadella Universitaria SS 554, Km. 4.500, 09042 MONSERRATO (CA), Italy desires to purchase same;

NOW, THEREFORE, in consideration of the sum of Five Dollars (\$5.00) and other good and valuable consideration paid by **Universita Degli Studi Di Cagliari**, the receipt and sufficiency of which are hereby acknowledged, I, PAULO LACOLLA, have sold, assigned, transferred and conveyed and by these presents do hereby sell, assign, transfer and convey unto **Universita Degli Studi Di Cagliari**, in and for the United States and its territories and for foreign countries, the entire right, title and interest in and to said provisional application and said application for United States Letters Patent, in and to the invention therein set forth and in and to any patent which may issue on said application for United States Letters Patent or any application, reissue, renewal, division, continuation or continuation-in-part thereof; or any foreign counterpart thereof or any other application that claims priority to the above-application, and I hereby bind myself, my heirs, legal representatives, administrators and assigns properly to execute without further consideration, any and all applications, petitions, oaths and assignments or other papers and instruments which may be necessary in order to carry into full force and effect the sale, assignment, transfer and conveyance hereby made or intended to be made.

IN WITNESS WHEREOF, I have hereunto set my hand and seal this 28 day of

June, 2001.



Paulo La Colla
PAULO LA COLLA

Orsola Macis
Witness

IL SEGRETARIO AMMINISTRATIVO
(Dott.ssa Orsola Macis)

06171.105013

ASSIGNMENT

WHEREAS, WE, PAULO LA COLLA, MARINO ARTICO, AND JEAN-PIERRE SOMMADOSSI, have invented certain improvements in "Phenylindoles for the Treatment of HIV" for which We/I have executed United States Provisional Application No. 60/283,393 which was filed on April 11, 2001; and

WHEREAS, **Universita Degli Studi Di Cagliari**, with a mailing address of Cittadella Universitaria SS 554, Km. 4.500, 09042 MONSERRATO (CA), Italy desires to purchase same;

NOW, THEREFORE, in consideration of the sum of Five Dollars (\$5.00) and other good and valuable consideration paid by **Universita Degli Studi Di Cagliari**, the receipt and sufficiency of which are hereby acknowledged, I, MARINO ARTICO, have sold, assigned, transferred and conveyed and by these presents do hereby sell, assign, transfer and convey unto **Universita Degli Studi Di Cagliari**, in and for the United States and its territories and for foreign countries, the entire right, title and interest in and to said provisional application and said application for United States Letters Patent, in and to the invention therein set forth and in and to any patent which may issue on said application for United States Letters Patent or any application, reissue, renewal, division, continuation or continuation-in-part thereof; or any foreign counterpart thereof or any other application that claims priority to the above-application, and I hereby bind myself, my heirs, legal representatives, administrators and assigns properly to execute without further consideration, any and all applications, petitions, oaths and assignments or other papers and instruments which may be necessary in order to carry into full force and effect the sale, assignment, transfer and conveyance hereby made or intended to be made.

IN WITNESS WHEREOF, I have hereunto set my hand and seal this 20 day of

June, 2001.



MARINO ARTICO

Witness

06171.105013

ASSIGNMENT

WHEREAS, WE, PAULO LA COLLA, MARINO ARTICO, AND JEAN-PIERRE SOMMADOSSI, have invented certain improvements in "Phenylindoles for the Treatment of HIV" for which We/I have executed United States Provisional Application No. 60/283,393 which was filed on April 11, 2001; and


WHEREAS, NOVIRIO PHARMACEUTICALS LIMITED, a Cayman Island corporation having an office at c/o Walker Secretaries, Walker House, Mary Street, Grand Cayman, Cayman Islands desires to purchase same;

NOW, THEREFORE, in consideration of the sum of Five Dollars (\$5.00) and other good and valuable consideration paid by NOVIRIO PHARMACEUTICALS LIMITED, the receipt and sufficiency of which are hereby acknowledged, I, JEAN-PIERRE SOMMADOSSI, have sold, assigned, transferred and conveyed and by these presents do hereby sell, assign, transfer and convey unto NOVIRIO PHARMACEUTICALS LIMITED, in and for the United States and its territories and for foreign countries, the entire right, title and interest in and to said provisional application and said application for United States Letters Patent, in and to the invention therein set forth and in and to any patent which may issue on said application for United States Letters Patent or any application, reissue, renewal, division, continuation or continuation-in-part thereof; or any foreign counterpart thereof or any other application that claims priority to the above-application, and I hereby bind myself, my heirs, legal representatives, administrators and assigns properly to execute without further consideration, any and all applications, petitions, oaths and assignments or other papers and instruments which may be necessary in order to carry into full force and effect the sale, assignment, transfer and conveyance hereby made or intended to be made.

06171.105013

IN WITNESS WHEREOF, I have hereunto set my hand and seal this 23rd day of

June, 2001.


JEAN-PIERRE SOMMADOSSI

On this 23rd day of June, 2001, before me, a notary public, came Jean-Pierre Sommadossi, to me known and known to be the individual described in and who executed the foregoing assignment, and he duly acknowledged the same to be his free act and deed.


Notary Public

(SEAL)

My commission expires: _____
CYNTHIA B. GAGNE
Notary Public
My Comm. Expires Sept. 25, 2003

06171.105013



UNITED STATES
PATENT AND
TRADEMARK OFFICE

OCTOBER 28, 2002

PTAS

Under Secretary of Commerce For Intellectual Property and
Director of the United States Patent and Trademark Office
Washington, DC 20231
www.uspto.gov

SHERRY M. KNOWLES, ESQ.
191 PEACHTREE STREET
ATLANTA, GA 30303-1763



102199601A

UNITED STATES PATENT AND TRADEMARK OFFICE
NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT DIVISION OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE MICROFILM COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE EMPLOYEE WHOSE NAME APPEARS ON THIS NOTICE AT 703-308-9723. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, ASSIGNMENT DIVISION, BOX ASSIGNMENTS, CG-4, 1213 JEFFERSON DAVIS HWY, SUITE 320, WASHINGTON, D.C. 20231.

RECORDATION DATE: 08/19/2002

REEL/FRAME: 013193/0841
NUMBER OF PAGES: 4

BRIEF: CHANGE OF NAME (SEE DOCUMENT FOR DETAILS).

ASSIGNOR:

NOVIRIO PHARMACEUTICALS LIMITED

DOC DATE: 05/28/2002

ASSIGNEE:

IDENIX PHARMACEUTICALS INC.
125 CAMBRIDGE PARK DR.
CAMBRIDGE, MASSACHUSETTS 02140

SERIAL NUMBER: 60132126
PATENT NUMBER:

FILING DATE: 04/30/1999
ISSUE DATE:

SERIAL NUMBER: 60096110
PATENT NUMBER:


FILING DATE: 08/10/1998
ISSUE DATE:

SERIAL NUMBER: 60131352
PATENT NUMBER:

FILING DATE: 04/28/1999
ISSUE DATE:

SERIAL NUMBER: 10022276
PATENT NUMBER:

FILING DATE: 12/14/2001
ISSUE DATE:



SERIAL NUMBER: 09459150
PATENT NUMBER: 6444652

FILING DATE: 12/10/1999
ISSUE DATE: 09/03/2002

SERIAL NUMBER: 10022148
PATENT NUMBER:

FILING DATE: 12/14/2001
ISSUE DATE:

SERIAL NUMBER: 09744038
PATENT NUMBER:

FILING DATE: 05/01/2001
ISSUE DATE:

SERIAL NUMBER: 60207538
PATENT NUMBER:

FILING DATE: 05/26/2000
ISSUE DATE:

SERIAL NUMBER: 09867110
PATENT NUMBER:

FILING DATE: 05/29/2001
ISSUE DATE:

SERIAL NUMBER: 60212100
PATENT NUMBER:

FILING DATE: 06/15/2000
ISSUE DATE:

SERIAL NUMBER: 09883033
PATENT NUMBER:

FILING DATE: 06/15/2001
ISSUE DATE:

SERIAL NUMBER: 60207674
PATENT NUMBER:

FILING DATE: 05/26/2000
ISSUE DATE:

SERIAL NUMBER: 60283276
PATENT NUMBER:

FILING DATE: 04/11/2001
ISSUE DATE:

SERIAL NUMBER: 09863816
PATENT NUMBER:

FILING DATE: 05/23/2001
ISSUE DATE:

SERIAL NUMBER: 60206585
PATENT NUMBER:

FILING DATE: 05/23/2000
ISSUE DATE:

SERIAL NUMBER: 09864078
PATENT NUMBER:

FILING DATE: 05/23/2001
ISSUE DATE:

SERIAL NUMBER: 60283393
PATENT NUMBER:

FILING DATE: 04/11/2001
ISSUE DATE:

SERIAL NUMBER: 10122252
PATENT NUMBER:

FILING DATE: 04/11/2002
ISSUE DATE:

SERIAL NUMBER: 60249532
PATENT NUMBER:

FILING DATE: 11/17/2000
ISSUE DATE:

SERIAL NUMBER: 10001868
PATENT NUMBER:

FILING DATE: 11/19/2001
ISSUE DATE:

SERIAL NUMBER: 60326184
PATENT NUMBER:

FILING DATE: 09/28/2001
ISSUE DATE:

SERIAL NUMBER: 60326192
PATENT NUMBER:

FILING DATE: 09/28/2001
ISSUE DATE:


013193/0841 PAGE 3

SERIAL NUMBER: 09371747
PATENT NUMBER: 6395716

FILING DATE: 08/10/1999
ISSUE DATE: 05/28/2002

PAULA MCCRAY, EXAMINER
ASSIGNMENT DIVISION
OFFICE OF PUBLIC RECORDS

08-22-2002



102199601

FORM-PTO-1595
1-31-92TRANSMITTAL OF DOCUMENTS
PATENTS ONLY

RDATION

Atty. Docket 06171.105004

To the Honorable Commissioner of Patents and Trademarks: Please record the attached original documents or copy thereof.

1. Name of conveying party(ies): Novirio Pharmaceuticals Limited *08/19/02*
 Additional name(s) of conveying party(ies) attached?
☐ Yes ☒ No

2. Name and address of receiving party(ies):

Name: Idenix Pharmaceuticals Inc.

Foreign Address:

Domestic Address: 125 Cambridge Park Dr.City: Cambridge State: MA ZIP: 02140

Additional name(s) & address(es) attached?

☐ Yes ☒ No

3. Nature of Conveyance:

☐ Assignment☐ Merger☐ Security Agreement☒ Change of Name

Other _____

Execution Date: 5/28/02

4. Application number (s) or patent numbers(s):

If this document is being filed together with a new application, the execution date of the application is:

A. Patent Application No.(s) see attached

B Patent Registration No. (s)

Additional numbers attached? ☒ Yes ☒ No

5. Name and address of party to whom correspondence concerning document should be mailed:

Name: Sherry M. Knowles, Esq.191 Peachtree StreetAtlanta, Georgia 30303-1763Telephone No.: 404- 572- 4600Facsimile No.: 404 572-51006. Number of applications and patents involved:
237. Total fee (37 CFR 3.41): \$ 920☒ Enclosed☒ Authorized to be charged to deposit account

8. Deposit account number

11-0980

(Attach duplicate copy of this page if paying by deposit account):

DO NOT USE THIS SPACE

9. Statement and signature.

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy of the original document.

Sally Sexton

Name of Person Signing

Signature

August 13, 2002

Date

Total number of pages comprising cover sheet: 13

08/21/2002 TDIAZ1 00000095 60132126

01 FC:581

920.00 OP


Schedule

TITLE & DOCKET NAME	COUNTRY	FILING DATE	SERIAL NUMBER	PATENT NUMBER	ISSUE DATE
IDX 1001: Provisional Use of 3'-Azido-2',3'- Dideoxyuridine	U.S.	04/30/99	60/132,126		
IDX 1000 Provisional β -L-2'-Deoxy- Nucleosides for the Treatment of Hepatitis B	U.S.	8/10/98	60/096,110		
	CON	04/28/99	60/131,352		
IDX 1000 Normal β -L-2'-Deoxy- Nucleosides for the Treatment of Hepatitis B	U.S.	8/10/99	09/371,747	6,395,716	5/28/02
IDX 1000CON β -L-2'-Deoxy- Nucleosides for the Treatment of Hepatitis B	U.S.	12/14/01	10/022,276		
IDX/1000 CIP β -L-2'-Deoxy- Nucleosides for the Treatment of Hepatitis B	U.S.	12/10/99	09/459,150		
IDX 1000 CIPCON β -L-2'-Deoxy- Nucleosides for the Treatment of Hepatitis B	U.S.	12/14/01	10/022,148		
IDX 1003 Substituted 6-Benzyl-4- Oxypyrimidines, Process for Their Preparation and Pharmaceutical Compositions Containing Them	US	07/17/99	09/744,038		
IDX 1004 Methods for Treating Hepatitis Delta Virus Infection with β - L-2' Deoxy-Nucleosides	U.S. Prov.	5/29/00	60/207,538		
	U.S.	5/29/01	09/867,110		
IDX 1005 3'-Prodrugs of 2'-deoxy- β -L- Nucleosides	U.S. Prov.	6/15/00	60/212,100		
	U.S.		09/883,033		
IDX1006 Methods and Compositions for Treating Flaviviruses and Pestiviruses	U.S. Prov.	5/26/00 4/11/01	60/207,674 60/283,276		
	U.S.	5/26/01	09/863,816		

TITLE & DOCKET NAME	COUNTRY	FILING DATE	SERIAL NUMBER	PATENT NUMBER	ISSUE DATE
IDX1007 Methods and Compositions for Treating Hepatitis C Virus	U.S. Prov.	05/23/00	60/206,585		
	U.S.	05/23/01	09/864,078		
IDX1008 Phenylindoles For The Treatment Of HIV	U.S. Prov.	4/11/01	60/283,393		
	U.S.	4/11/02	10/122,252		
IDX1009 Methods for Inhibiting the Transmission of HIV Using Topically Applied Substituted 6-Benzyl-4-Oxopyrimidines	U.S. Prov.	11/17/00	60/249,532		
	U.S.	11/19/01	10/001,868		
IDX1013 Methods and Compositions for Treating Hepatitis C Virus	U.S. Prov.	9/28/01	60/326,184		
IDX1014 Methods and Compositions for Treating Flaviviruses and Pestiviruses	U.S. Prov.	9/28/01	60/326,192		

CR-81404

Certificate of Incorporation On Change Of Name



I DO HEREBY CERTIFY that
NOVIRIO PHARMACEUTICALS LIMITED

having by Special Resolution dated 28th of May 2002
changed its name to now incorporated under the name of

Idenix Pharmaceuticals, Inc.

Given under my hand and Seal at George Town in the
Island of Grand Cayman this Twenty-Eighth day of May
Two Thousand Two
(SGD. J.D.B. DIXON)

CERTIFIED TRUE COPY

CERTIFIED TO BE A TRUE AND CORRECT COPY

SGD.

JOSEPH H. DIXON
Agent Registrar of Companies

Date 28th May, 2002

WALKERS


ATTORNEYS-AT-LAW
WALKER HOUSE, GEORGE TOWN
GRAND CAYMAN, CAYMAN ISLANDS

DATE:

5/7/2002

CERTIFICATE OF MAILING (37 CFR § 1.8a)

I hereby certify that this Recordation of Assignment, along with any other paper referred to as being attached or enclosed, is being deposited with the United States Postal Service on the date shown below with sufficient postage as first-class mail in an envelope addressed to the Box Assignment, Assistant Commissioner for Patents, Washington, D.C. 20231.


Sally Sexton

06171.105004
Date: August 13, 2002



UNITED STATES
PATENT AND
TRADEMARK OFFICE

C-2

JUNE 11, 2003

PTAS

Under Secretary of Commerce For Intellectual Property and
Director of the United States Patent and Trademark Office
Washington, DC 20231
www.uspto.gov

SHERRY M. KNOWLES, ESQ.
191 PEACHTREE STREET
ATLANTA, GA 30303-1763



102359457A

UNITED STATES PATENT AND TRADEMARK OFFICE
NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT DIVISION OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE MICROFILM COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE EMPLOYEE WHOSE NAME APPEARS ON THIS NOTICE AT 703-308-9723. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, ASSIGNMENT DIVISION, BOX ASSIGNMENTS, CG-4, 1213 JEFFERSON DAVIS HWY, SUITE 320, WASHINGTON, D.C. 20231.

RECORDATION DATE: 02/06/2003

REEL/FRAME: 013718/0543
NUMBER OF PAGES: 7

BRIEF: CERTIFICATE OF DOMESTICATION INCORPORATION IN DELAWARE

ASSIGNOR:

NOVIRIO PHARMACEUTICALS LIMITED

DOC DATE: 05/30/2002

ASSIGNEE:

IDENIX PHARMACEUTICALS INC.
125 CAMBRIDGE PARK DR.
CAMBRIDGE, MASSACHUSETTS 02140

SERIAL NUMBER: 60096110 - 105002
PATENT NUMBER:

FILING DATE: 08/10/1998
ISSUE DATE:

SERIAL NUMBER: 60131352 - 105002
PATENT NUMBER:

FILING DATE: 04/28/1999
ISSUE DATE:

SERIAL NUMBER: 10022276 - 105030
PATENT NUMBER: 6569837

FILING DATE: 12/14/2001
ISSUE DATE: 05/27/2003

SERIAL NUMBER: 10022148 10x1000
PATENT NUMBER: 6566344

FILING DATE: 12/14/2001
ISSUE DATE: 05/20/2003

VDH Rec'd

JUN 17 2003

SERIAL NUMBER: 60207538 - 105011
PATENT NUMBER:

FILING DATE: 05/26/2000
ISSUE DATE:

SERIAL NUMBER: 09867110 - 105021
PATENT NUMBER:

FILING DATE: 05/29/2001
ISSUE DATE:

SERIAL NUMBER: 60212100 - 105012
PATENT NUMBER:

FILING DATE: 06/15/2000
ISSUE DATE:

SERIAL NUMBER: 09883033 - 105026
PATENT NUMBER:

FILING DATE: 06/15/2001
ISSUE DATE:

SERIAL NUMBER: 60207674 - 105008
PATENT NUMBER:

FILING DATE: 05/26/2000
ISSUE DATE:

SERIAL NUMBER: 60283276 - 105008
PATENT NUMBER:

FILING DATE: 04/11/2001
ISSUE DATE:

SERIAL NUMBER: 09863816 - 105027
PATENT NUMBER:

FILING DATE: 05/23/2001
ISSUE DATE:

SERIAL NUMBER: 60206585 - 105009
PATENT NUMBER:

FILING DATE: 05/23/2000
ISSUE DATE:

SERIAL NUMBER: 09864078 - 105022
PATENT NUMBER:

FILING DATE: 05/23/2001
ISSUE DATE:

SERIAL NUMBER: 60283393 - 105013
PATENT NUMBER:

FILING DATE: 04/11/2001
ISSUE DATE:

SERIAL NUMBER: 10122252 - 105033
PATENT NUMBER:

FILING DATE: 04/11/2002
ISSUE DATE:

SERIAL NUMBER: 60249532 - 105014
PATENT NUMBER:

FILING DATE: 11/17/2000
ISSUE DATE:

SERIAL NUMBER: 10001868 - 105030
PATENT NUMBER: 6545007

FILING DATE: 11/19/2001
ISSUE DATE: 04/08/2003

SERIAL NUMBER: 60326184 - 105018
PATENT NUMBER:

FILING DATE: 09/28/2001
ISSUE DATE:

SERIAL NUMBER: 60326192 - 105020
PATENT NUMBER:

FILING DATE: 09/28/2001
ISSUE DATE:

SERIAL NUMBER: 09371747 - 105005
PATENT NUMBER: 6395716

FILING DATE: 08/10/1999
ISSUE DATE: 05/28/2002

SERIAL NUMBER: 09459150 - 105007
PATENT NUMBER: 6444652

FILING DATE: 12/10/1999
ISSUE DATE: 09/03/2002

013718/0543 PAGE 3

SAUNDRA BALLENGER, EXAMINER
ASSIGNMENT DIVISION
OFFICE OF PUBLIC RECORDS

02-07-2003



102359457

FORM-PTO-1595
1-31-92TRANSMITTAL OF DOCUMENT FOR RECORDATION
PATENTS ONLYAtty. Docket 06171.105084²

To the Honorable Commissioner of Patents and Trademarks: Please record the attached original documents or copy thereof.

1. Name of conveying party(ies): Novirio
Pharmaceuticals Limited
Additional name(s) of conveying party(ies) attached?
☐ Yes ☒ No

2-6-03

2. Name and address of receiving party(ies):

Name: Idenix Pharmaceuticals Inc.

Foreign Address:

Domestic Address: 125 Cambridge Park Dr.City: Cambridge State: MA ZIP: 02140

Additional name(s) & address(es) attached?

☐ Yes ☒ No

3. Nature of Conveyance:

☐ Assignment☐ Merger☐ Security Agreement☐ Change of Name☒ Other Certificate of Domestication:
incorporation in DelawareExecution Date: 5/30/02

4. Application number (s) or patent numbers(s):

If this document is being filed together with a new application, the execution date of the application is:

A. Patent Application No.(s)

B Patent Registration No. (s)

Additional numbers attached? ☒ Yes ☐ No

5. Name and address of party to whom correspondence concerning document should be mailed:

Name: Sherry M. Knowles, Esq.191 Peachtree StreetAtlanta, Georgia 30303-1763Telephone No.: 404- 572- 4600Facsimile No.: 404 572-51006. Number of applications and patents involved:
227. Total fee (37 CFR 3.41): \$ 880☒ Enclosed☐ Authorized to be charged to deposit account

8. Deposit account number

11-0980

(Attach duplicate copy of this page if paying by deposit account):

DO NOT USE THIS SPACE

9. Statement and signature.

*To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy of the original document.*Sally Sexton

Name of Person Signing

Sally Sexton

Signature

January 30, 2003

Date

Total number of pages comprising cover sheet: 3

OFFICE OF PUBLIC RECORDS

FINANCE SECTION

2003 FEB - 6 11 3:03

02/07/2003 EXDUPER 00000082 600%110

01 FC:8021

880.00 UP

Idenix Pharmaceuticals Patent Docket

TITLE & DOCKET NAME	COUNTRY	FILING DATE	SERIAL NUMBER	PATENT NUMBER	ISSUE DATE
IDX 1000 Provisional β -L-2'-Deoxy- Nucleosides for the Treatment of Hepatitis B	U.S.	8/10/98	60/096,110		
	CON	04/28/99	60/131,352		
IDX 1000 Normal β -L-2'-Deoxy- Nucleosides for the Treatment of Hepatitis B	U.S.	8/10/99	09/371,747	6,395,716	5/28/02
IDX 1000CON β -L-2'-Deoxy- Nucleosides for the Treatment of Hepatitis B	U.S.	12/14/01	10/022,276		
IDX/1000 CIP β -L-2'-Deoxy- Nucleosides for the Treatment of Hepatitis B	U.S.	12/10/99	09/459,150	6,444,652	9/3/02
IDX 1000 CIPCON β -L-2'-Deoxy- Nucleosides for the Treatment of Hepatitis B	U.S.	12/14/01	10/022,148		
IDX 1004 Methods for Treating Hepatitis Delta Virus Infection with β- L-2' Deoxy-Nucleosides	U.S. Prov.	5/29/00	60/207,538		
	U.S.	5/29/01	09/867,110		
IDX 1005 3'-Prodrugs of 2'-deoxy-β-L- Nucleosides	U.S. Prov.	6/15/00	60/212,100		
	U.S.		09/883,033		
IDX1006 Methods and Compositions for Treating Flaviviruses and Pestiviruses	U.S. Prov.	5/26/00 4/11/01	60/207,674 60/283,276		
	U.S.	5/26/01	09/863,816		
IDX1007 Methods and Compositions for Treating Hepatitis C Virus	U.S. Prov.	05/23/00	60/206,585		
	U.S.	05/23/01	09/864,078		
IDX1008 Phenylindoles For The Treatment Of HIV	U.S. Prov.	4/11/01	60/283,393		
	U.S.	4/11/02	10/122,252		

TITLE & DOCKET NAME	COUNTRY	FILING DATE	SERIAL NUMBER	PATENT NUMBER	ISSUE DATE
IDX1009 Methods for Inhibiting the Transmission of HIV Using Topically Applied Substituted 6-Benzyl-4- Oxopyrimidines	U.S. Prov.	11/17/00	60/249,532		
	U.S.	11/19/01	10/001,868		
IDX1013 Methods and Compositions for Treating Hepatitis C Virus	U.S. Prov.	9/28/01	60/326,184		
IDX1014 Methods and Compositions for Treating Flaviviruses and Pestiviruses	U.S. Prov.	9/28/01	60/326,192		

FROM

(THU) 5.30'02 7:59/ST.

STATE OF DELAWARE
DIVISION OF CORPORATIONS
FILED 08:00 AM 05/30/2002
020342271 - 3530324

**CERTIFICATE OF DOMESTICATION
OF
IDENIX PHARMACEUTICALS, INC.**

It is hereby certified that:

1. Idenix Pharmaceuticals, Inc. (hereinafter called the "corporation") was first formed, incorporated, or otherwise came into being on May 1, 1998 in the jurisdiction of the Cayman Islands.
2. The name of the corporation immediately prior to the filing of this certificate of domestication pursuant to the provisions of Section 388 of the General Corporation Law of the State of Delaware is Idenix Pharmaceuticals, Inc.
3. The name of the corporation as set forth in its certificate of incorporation to be filed concomitantly with this certificate of domestication in accordance with subsection (b) of Section 388 of the General Corporation Law of the State of Delaware is Idenix Pharmaceuticals, Inc.
4. The jurisdiction that constituted the seat, siege social, or principal place of business or central administration of the corporation, or other equivalent thereto under applicable law immediately prior to the filing of this certificate of domestication pursuant to the provisions of Section 388 of the General Corporation Law of the State of Delaware is the jurisdiction of the Cayman Islands.
5. The undersigned is a corporation, officer, director, trustee, manager, partner, or other person performing functions equivalent to those of an officer or director, however named or described, and is authorized to sign this certificate of domestication on behalf of the corporation.
6. This certificate of domestication shall be effective at 9:00 a.m. on May 30, 2002.

Dated: May 30, 2002


/s/ Jean-Pierre Sommadossi
Jean Pierre-Sommadosi
Chief Executive Officer,
Idenix Pharmaceuticals, Inc.

CERTIFICATE OF DOMESTICATION
OF
IDENIX PHARMACEUTICALS, INC.

It is hereby certified that:

1. Idenix Pharmaceuticals, Inc. (hereinafter called the "corporation") was first formed, incorporated, or otherwise came into being on May 1, 1998 in the jurisdiction of the Cayman Islands.
2. The name of the corporation immediately prior to the filing of this certificate of domestication pursuant to the provisions of Section 388 of the General Corporation Law of the State of Delaware is Idenix Pharmaceuticals, Inc.
3. The name of the corporation as set forth in its certificate of incorporation to be filed concomitantly with this certificate of domestication in accordance with subsection (b) of Section 388 of the General Corporation Law of the State of Delaware is Idenix Pharmaceuticals, Inc.
4. The jurisdiction that constituted the seat, siege social, or principal place of business or central administration of the corporation, or other equivalent thereto under applicable law immediately prior to the filing of this certificate of domestication pursuant to the provisions of Section 388 of the General Corporation Law of the State of Delaware is the jurisdiction of the Cayman Islands.
5. The undersigned is a corporation, officer, director, trustee, manager, partner, or other person performing functions equivalent to those of an officer or director, however named or described, and is authorized to sign this certificate of domestication on behalf of the corporation.
6. This certificate of domestication shall be effective at 9:00 a.m. on May 30, 2002.

Dated: May 30, 2002



Jean Pierre-Sommadossi
Chief Executive Officer,
Idenix Pharmaceuticals, Inc.

Registrar of Companies,
Tower Building,
Grand Cayman.

Dear Sir,

IDENIX PHARMACEUTICALS, INC.

I, Andrea J. Corcoran, of 61 Garfield Street, Cambridge, MA 0218, being a director of Idenix Pharmaceuticals, Inc. (the "Company"), an exempted company incorporated under the Companies Law (2001 Second Revision), DO HEREBY make application, pursuant to Section 226 of the Companies Law (2001 Second Revision) for the Company to be deregistered in the Cayman Islands.

In support of this application:

1. I would advise that the Company has been accepted for domestication pursuant to Section 388 of the General Corporation Law of the State of Delaware, the United States of America. A copy of the Certificate of Domestication is attached to this application. I confirm that the laws of the State of Delaware, the United States of America permit the transfer of the Company to that jurisdiction and indeed that is the effect of the domestication procedure.
2. I enclose payment of US\$2,414.63 (CIS1980) in respect of the fee for deregistration.
3. I confirm that the Company does not propose to change its name following deregistration.
4. I confirm that the Company has no secured creditors.
5. I confirm that the Company is not and has never been licensed under the provisions of the Banks and Trust Companies Law, (2001 Revision) or the Insurance Law, (2001 Revision).

I attach to this application

1. a certified copy of the Special Resolution of the Company adopted on ____ May 2002 resolving to register the Company by way of continuation in the State of Delaware, the United States of America;
2. a certified copy of the Resolution adopted by the Board of Directors of the Company dated May 6, 2002 resolving to apply for deregistration pursuant to Section 226 of the Companies Law (2001 Second Revision) and authorising me to make this application on behalf of the Company; and
3. my affidavit in support of this application in the terms prescribed by section 226(3) of the Companies Law (2001 Second Revision).

DATED this day of May 2002


Andrea J. Corcoran

Director
IDENIX PHARMACEUTICALS, INC.

Delaware


PAGE 1

The First State

I, HARRIET SMITH WINDSOR, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF DOMESTICATION OF "IDENIX PHARMACEUTICALS, INC.", FILED IN THIS OFFICE THE THIRTIETH DAY OF MAY, A.D. 2002, AT 8 O'CLOCK A.M.

AND I DO HEREBY FURTHER CERTIFY THAT THE EFFECTIVE DATE OF THE AFORESAID CERTIFICATE OF DOMESTICATION IS THE THIRTIETH DAY OF MAY, A.D. 2002, AT 9 O'CLOCK A.M.

A FILED COPY OF THIS CERTIFICATE HAS BEEN FORWARDED TO THE NEW CASTLE COUNTY RECORDER OF DEEDS.



Harriet Smith Windsor
Harriet Smith Windsor, Secretary of State

3530324 8100D

AUTHENTICATION: 1802262

020342271

DATE: 05-30-02